プロセプト・バイオロボティクスに関するコメント

Upgrades
• $アロジーン・セラピューティクス(ALLO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $チャンピオンX・コーポレーション(CHX.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX(CSX.US)$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
•$テクニップFMC(FTI.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $ノーフォーク・サザン(NSC.US)$ : Stifel Upgrades to Buy from Hold - PT $2...

$プロセプト・バイオロボティクス(PRCT.US)$ 50 today?

IPOs see strong demand as investors are seeking new companies that offer innovative products and services in wide ranging and diverse areas. A number of well received IPOs have enjoyed terrific returns which could be attributed to market exuberance over these new listings. This comes as no surprise as the US market is the mainstay of most global portfolios of investors and also home to multiple fast growing companies across various industries. With the market reaching new all time highs, concerns are increasing about new listings overheating. The newly listed companies also tend to be more volatile during their first few earnings seasons as market expectations will rest on if they could deliver the promised targets. Investors need to be aware that early institutional investors look to exit their holdings within a year or so while retail investors are buying in, which results in increased volatility. Investment decisions should always be guided by a fundamental analysis of the company and its valuation to ensure that investors are not taking unnecessary risks to their portfolios by jumping on this IPO bandwagon blindly.
$ディフィニティブ・ヘルスケア(DH.US)$
$DICE THERAPEUTICS, INC.(DICE.US)$
$ダッチ・ブロス(BROS.US)$
$オン・ホールディング(ONON.US)$
$プロセプト・バイオロボティクス(PRCT.US)$
$スポートレーダー・グループ(SRAD.US)$
$ソートワークス・ホールディング(TWKS.US)$
$タイラ・バイオサイエンシズ(TYRA.US)$

$プロセプト・バイオロボティクス(PRCT.US)$
lets do that by friday
$ソネット・バイオセラピューティクス・ホールディングス(SONN.US)$
$エディソン・ネーション(BBIG.US)$
$エータイヤ・ファーマ(LIFE.US)$

$プロセプト・バイオロボティクス(PRCT.US)$ let go to$120